Trends in Next-Generation Sequencing

XIFIN recently teamed up with William Blair and The Dark Report to conduct a survey to better understand next-generation sequencing trends in the clinical lab space. Here is a general overview of the findings.

Out of 186 responses, the majority of responses were from independent labs (46%) and hospital health systems (40%) with the other 14% being spread out amongst academic centers (7%), tertiary centers (2%) and physician offices (5%).  

Beyond the demographic data, William Blair also provided nine major conclusions found after conducting this survey:

  1. Illumina maintains its leading position based on current installed bases, although newer platforms are starting to crop up
  2. Overall sentiment around investment in NGS instrumentation and reagents/ consumable over the next 12 months and over the next two to three years continues to be quite bullish.
  3. NovaSeq was the most popular platform cited for purchase in the near term (within a year) and Thermo Fisher’s [TMO $210.91] Ion S5 was the most cited platform for longer-term purchases.
  4. Most users that indicated plans to buy instrumentation currently operate NGS.
  5. Respondent plans after the Medicare NGS NCD were variable.
  6. Of those that expect to add tests as a result of the NCD, chosen methodology also varies.
  7. At a high level, reimbursement expectations across all payer categories were slightly more positive than expected.
  8. Expectations for revenue growth opportunities.
  9. When asked about potential partnerships, the number of respondents that indicated this was likely was surprising to us, given the Medicare reimbursement environment.


For a full overview of this survey’s results, download the report

Published by XIFIN
Share This Post:

Sign Up for Blog Alerts

Search Blog Posts

Blog Posts By Date

Blog Posts By Tag